Gossamer’s Seralutinib NDA Plans Intact After FDA Clears Filing Path
After months of regulatory uncertainty following its Phase III PROSERA study's missed statistical threshold, the FDA's feedback on seralutinib is a shot in the arm for Gossamer.
Scrip - July 28, 2026

GSK Cuts Costs With Phase III Starts Set To Double
The company now expects over 20 late-stage trials to begin this year and is targeting annual cost savings of £1.9bn to pay for them.
Scrip - July 28, 2026

Sarepta Taps Outsider CEO As Exon-Skippers Face Key Test
Sarepta has named former AbbVie R&D leader Michael Severino CEO ahead of a crucial FDA decision on whether failed confirmatory trials will cost Amondys 45 and Vyondys 53 their accelerated approval status.
Scrip - July 28, 2026

As Tech Stocks Tumble, AstraZeneca Reins In AI Spending
A long-awaited sell-off of AI company stocks has arrived; is this also a wake-up call for big pharma’s spending spree on the technology?
Scrip - July 28, 2026

Stock Watch: Why Novartis Stock Rose On Results Half As Good As J&J’s
Novartis grew sales at less than half J&J's rate in Q2, yet investors reacted more warmly — a result explained less by the numbers than the residual of Entresto's sales left to erode.
Scrip - July 28, 2026

Late To The Party: Can Cipla’s Generic Advair Catch Up In The US Market?
Cipla is set to enter the multi-player generic Advair race in the US, but market dynamics appear to have tempered revenue expectations. Can the Indian firm carve out a meaningful slice of the market?
Scrip - July 28, 2026

CSPC’s Novel Antidepressant Hits Mark In First-Line China Phase III Trial
CSPC's ammoxetine beats placebo and was numerically superior to Zoloft in a Chinese Phase III trial for the first-line treatment of depression.
Scrip - July 28, 2026

Chugai Fortifies Investment Function Amid Successful H1
After establishing multiple investment arms globally, the major Japanese firm has set up a new Tokyo-based team to potentially direct a portion of growing revenues into M&As and other transactions.
Scrip - July 28, 2026

Boston Scientific Halts Enroute TCAR Systems Over Arterial Sheath Issue
Boston Scientific is telling customers to stop using Enroute Transcarotid Neuroprotection System and Enroute Transcarotid Neuroprotection System Plus. The devices, which help prevent stroke during treatment of carotid artery disease, may come apart during use.
Medtech Insight - July 27, 2026

FDA Approves Colorectal Cancer Blood Test From Freenome And Abbott
The US Food and Drug Administration has approved SimpleScreen CRC, a blood-based colorectal cancer screening test developed by Freenome that Abbott will exclusively commercialize in the US for average-risk adults aged 45 and older. The test detects cell-free DNA signals linked to colorectal cancer.
Medtech Insight - July 27, 2026

Women’s Oncology Market Expected To Reach $110Bn By 2030, Gynecologic Cancers Remain Underfunded
A new PwC report finds women's oncology heading toward $110bn by 2030, yet ovarian and endometrial cancers receive a fraction of breast cancer's NIH funding. Liquid biopsy, AI screening tools, and $6.5bn in private investment aim to close the gap.
Medtech Insight - July 27, 2026

German Medtech Innovation Decision Signals A Crack In Industry-Government ‘Dialog’
Germany’s medtech industry said it is frustrated by outgoing health minister Warken’s last-minute decision to limit temporary reimbursement and access for new diagnostic and treatment methods (NUB). Spectaris’ medtech head Marcus Kuhlmann criticized the purely money saving initiative.
Medtech Insight - July 27, 2026

WHO Names First Medtech Regulators Ready For Listed Authority Status
The World Health Organization is expanding its framework for recognizing trusted regulators into medtech, which it hopes will foster global regulatory cooperation.
Medtech Insight - July 27, 2026

Acute Care AI Pioneer Viz.ai Takes First Step Into Chronic Brain Disease
Viz.ai is expanding beyond acute care into neurodegenerative disease, partnering with Cortechs.ai to bring quantitative brain MRI analysis into its 2,000-hospital network — with MS as the entry point and broader ambitions to follow.
Medtech Insight - July 27, 2026

CareDx CEO On Precision Diagnostics Pivot, Oncology Expansion
CareDx CEO John Hanna details the twin deals — a $171.2m lab products divestiture and the up-to-$260m Naveris buy — that recast the transplant-diagnostics firm as a molecular diagnostics company betting on reimbursed, repeat-tested oncology niches led by the Medicare-covered NavDx.
Medtech Insight - July 27, 2026

Beauty Brand ‘AI Visibility’ Shaped by Editorial Media, Retailers
AI is reshaping beauty discovery, with brands gaining visibility by building authority across editorial media, retailer ecosystems and other third-party sources that influence how AI platforms generate recommendations.
HBW Insight - July 28, 2026

As Cipla Chases US Milestone, Generic Ventolin Scale-up Is Key
Cipla's $1bn US revenue target by end-FY27 hinges on a handful of high-stakes bets — generic Ventolin scaling quickly and approvals for products like generic Advair and a peptide which it sees as a significant opportunity.
Generics Bulletin - July 28, 2026

Merck Signs License Agreements For Monthly PrEP Drug Alimatravir In Developing Countries
The company reached agreements with generic drugmakers to supply the drug in 129 low- and middle-income countries that account for a significant share of global HIV burden.
Generics Bulletin - July 28, 2026

FDA Approves Amneal’s Generic Omnipaque With Four New Iohexol Presentations
The US FDA has approved Amneal’s Iohexol, a radiographic contrast agent that a mere few months ago was facing reported product shortages.
Generics Bulletin - July 28, 2026

Sun Opens Up South African GLP-1 Competition With Semaglutide Launch
Sun has confirmed the launch of its generic semaglutide for diabetes in South Africa, just a couple of weeks after receiving approval.
Generics Bulletin - July 28, 2026

Brexit Mutual Recognition Loss Still Raises Costs For UK Generics Manufacturers, Conference Hears
At Medicines UK’s annual London conference, experts discussed how industry is working to secure the UK’s medicines future, especially when it comes to the lasting impacts created by the 2016 Brexit referendum, in which the country voted to leave the European Union.
Generics Bulletin - July 28, 2026

Cipla Joins Generic Advair Club With FDA Approval
Cipla has delivered on its filing for a US Advair generic, garnering a long-sought FDA approval. But with several other players in the US market, the dynamic will be crowded.
Generics Bulletin - July 28, 2026

Accord’s Late Launch Still Raises Stakes In Denosumab Battle
Accord has launched interchangeable Prolia and Xgeva biosimilars Osvyrti and Jubereq in the US, entering a crowded denosumab market with Cigna formulary support, patient assistance and pricing designed to challenge Amgen’s established brands.
Generics Bulletin - July 28, 2026

The Generics Bulletin Top 50, Part Two: Fresh Data Shakes Up Mid-Table Players
In the second part of this year’s Generics Bulletin Top 50, we see Apotex join our rankings for the first time, after the company released detailed financial data as part of its recent IPO. How will this shake up our middle table?
Generics Bulletin - July 28, 2026

Peer Groups, Not Performance: What Really Drives Large Pharma CEO Pay
CEOs of $10bn–$40bn pharma companies averaged $14.9m in 2025, a 36% discount to the $23.1m big pharma mean. But strip out the non-US firms and the gap nearly closes: the discount is mostly geography, with US chiefs paid up to four times their Japanese and European peers at similar-sized companies.
In Vivo - July 27, 2026